Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma

被引:24
|
作者
Jiang, Lei [1 ]
Li, Luan [2 ]
Liu, Yongzhuang [3 ]
Lu, Ligong [1 ]
Zhan, Meixiao [1 ]
Yuan, Shengtao [3 ]
Liu, Yanyan [1 ]
机构
[1] Jinan Univ, Zhuhai Peoples Hosp, Guangdong Prov Key Lab Tumor Intervent Diag & Trea, Zhuhai Hosp, Zhuhai, Guangdong, Peoples R China
[2] Nanjing Med Univ, Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Affiliated Canc Hosp, Nanjing, Jiangsu, Peoples R China
[3] China Pharmaceut Univ, Jiangsu Key Lab Drug Screening, Nanjing, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
hepatocellular carcinom; drug resistance; sorafenib; lenvatinib; regorafenib; cabozantinib; TIVANTINIB ARQ 197; OVERCOMES SORAFENIB RESISTANCE; CANCER STEM-CELL; ACQUIRED-RESISTANCE; 2ND-LINE THERAPY; C-MET; LENVATINIB; ANGIOGENESIS; ACTIVATION; PATHWAY;
D O I
10.3389/fphar.2023.1097277
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, and it usually occurs following chronic liver disease. Although some progress has been made in the treatment of HCC, the prognosis of patients with advanced HCC is not optimistic, mainly because of the inevitable development of drug resistance. Therefore, multi-target kinase inhibitors for the treatment of HCC, such as sorafenib, lenvatinib, cabozantinib, and regorafenib, produce small clinical benefits for patients with HCC. It is necessary to study the mechanism of kinase inhibitor resistance and explore possible solutions to overcome this resistance to improve clinical benefits. In this study, we reviewed the mechanisms of resistance to multi-target kinase inhibitors in HCC and discussed strategies that can be used to improve treatment outcomes.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies
    Galun, Danijel
    Srdic-Rajic, Tatjana
    Bogdanovic, Aleksandar
    Loncar, Zlatibor
    Zuvela, Marinko
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2017, 4 : 93 - 103
  • [32] The Latest Overview of circRNA in the Progression, Diagnosis, Prognosis, Treatment, and Drug Resistance of Hepatocellular Carcinoma
    Xiong, Dandan
    He, Rongquan
    Dang, Yiwu
    Wu, Huayu
    Feng, Zhenbo
    Chen, Gang
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [33] The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance
    Ruzickova, Eliska
    Skoupa, Nikola
    Dolezel, Petr
    Smith, Dennis A.
    Mlejnek, Petr
    BIOMOLECULES, 2019, 9 (11)
  • [34] Research Progress on the Drug Resistance of ALK Kinase Inhibitors
    Li, Zhen
    Liu, Fang
    Wu, Shuang
    Ding, Shi
    Chen, Ye
    Liu, Ju
    CURRENT MEDICINAL CHEMISTRY, 2022, 29 (14) : 2456 - 2475
  • [35] A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma
    Guan, Renguo
    Yu, Chengyou
    Li, Shaohua
    Mei, Jie
    Wei, Wei
    Guo, Rongping
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [36] Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma
    Golkowski, Martin
    Lau, Ho-Tak
    Chan, Marina
    Kenerson, Heidi
    Vidadala, Venkata Narayana
    Shoemaker, Anna
    Maly, Dustin J.
    Yeung, Raymond S.
    Gujral, Taranjit S.
    Ong, Shao-En
    CELL SYSTEMS, 2020, 11 (02) : 196 - +
  • [37] Role of microRNAs in the development of hepatocellular carcinoma and drug resistance
    Tricoli, Lucas
    Niture, Suresh
    Chimeh, Uche
    Ressom, Habtom
    Kumar, Deepak
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2019, 24 : 382 - 391
  • [38] Drug Resistance and Endoplasmic Reticulum Stress in Hepatocellular Carcinoma
    Khaled, Jaafar
    Kopsida, Maria
    Lennernaes, Hans
    Heindryckx, Femke
    CELLS, 2022, 11 (04)
  • [39] Kinase inhibitors in the treatment of renal cell carcinoma
    Larkin, James M. G.
    Eisen, Tim
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 (03) : 216 - 226
  • [40] The role of microRNA in the resistance to treatment of hepatocellular carcinoma
    Pratama, Muhammad Yogi
    Pascut, Devis
    Massi, Muhammad Nasrum
    Tiribelli, Claudio
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (20)